&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-11-19, 21:59

Marks & Spencer Launches Re:Spark to Ignite Renewable Electricity Adoption Across Its Fashion Supply Chain
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-10-07, 10:32

From Data to Dialogue: Singapore PR Professionals Explore AI's Role in Next-Gen Communications at IPRS - Notified Panel Discussion
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-26, 17:29

Bitget Releases September 2025 Proof of Reserves, Leading with 186% Reserve Ratio and UEX Security Innovations
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-18, 00:05

Zoom Cares commits $10M to democratize AI education and expand opportunity
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-17, 03:30

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-09, 19:00

Cority Hires Sustainability Expert to Help Companies Shift Focus from Reporting to Value Generation
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-09-02, 16:00

$152 Billion and Rising: New Report Shows Insurance Industry Facing Growing Average Annual Losses from Natural Catastrophes
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-08-19, 18:59

VCI Global Announces US$2 Billion Partnership Secured by Sovereign-Grade Encrypted Infrastructure
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-08-15, 21:00

Bitget Kicks Off the New 2025/26 LALIGA Season with “Back in Play, Bitget Way”
Jannie Boothby

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-08-09, 02:25

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
Jannie Boothby

Notified -

Popular Posts